Mediar Therapeutics raised $75.7 million to advance MTX-463, an FDA-designated orphan drug antibody for the treatment of idiopathic pulmonary fibrosis, a rare and progressive scarring disease of the lungs.
Mediar Therapeutics raised $75.7 million to advance MTX-463, an FDA-designated orphan drug antibody for the treatment of idiopathic pulmonary fibrosis, a rare and progressive scarring disease of the lungs.